Have a feature idea you'd love to see implemented?
Let us know!
BOLT Bolt Biotherapeutics Inc
Price (delayed)
$0.5
Market cap
$19.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.71
Enterprise value
$27.16M
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach
Highlights
The debt has contracted by 13% YoY and by 3.8% from the previous quarter
The EPS has grown by 10% YoY
Bolt Biotherapeutics's gross profit has increased by 36% YoY but it has decreased by 12% from the previous quarter
The revenue rose by 36% YoY but it fell by 12% QoQ
The quick ratio has plunged by 53% YoY and by 28% from the previous quarter
The equity is down by 44% YoY and by 16% from the previous quarter
Key stats
What are the main financial stats of BOLT
Market
Valuations
Earnings
Shares outstanding
38.27M
Market cap
$19.14M
Enterprise value
$27.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.27
Price to sales (P/S)
1.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.78
Revenue
$9.78M
Gross profit
$9.78M
Net income
-$65.09M
EBIT
-$65.09M
EBITDA
-$60.14M
Free cash flow
-$61.02M
Per share
Balance sheet
Liquidity
EPS
-$1.71
EPS diluted
-$1.71
Free cash flow per share
-$1.6
Book value per share
$1.88
Revenue per share
$0.26
TBVPS
$2.86
Total assets
$109.33M
Total liabilities
$37.3M
Debt
$18.18M
Equity
$72.03M
Working capital
$39.06M
Debt to equity
0.25
Current ratio
3.16
Quick ratio
3.02
Net debt/EBITDA
-0.13
Margins
Efficiency
Dividend
EBITDA margin
-615%
Gross margin
100%
Net margin
-665.6%
Operating margin
-776.1%
Return on assets
-48.6%
Return on equity
-69.5%
Return on invested capital
-51.6%
Return on capital employed
-71.3%
Return on sales
-665.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BOLT stock price
How has the Bolt Biotherapeutics stock price performed over time
Intraday
-0.7%
1 week
-5.29%
1 month
-12.28%
1 year
-50.5%
YTD
-55.36%
QTD
-22.84%
Financial performance
How have Bolt Biotherapeutics's revenue and profit performed over time
Revenue
$9.78M
Gross profit
$9.78M
Operating income
-$75.9M
Net income
-$65.09M
Gross margin
100%
Net margin
-665.6%
Bolt Biotherapeutics's gross profit has increased by 36% YoY but it has decreased by 12% from the previous quarter
The revenue rose by 36% YoY but it fell by 12% QoQ
The net margin has grown by 33% YoY but it has contracted by 12% from the previous quarter
Bolt Biotherapeutics's operating margin has increased by 28% YoY but it has decreased by 12% from the previous quarter
Growth
What is Bolt Biotherapeutics's growth rate over time
Valuation
What is Bolt Biotherapeutics stock price valuation
P/E
N/A
P/B
0.27
P/S
1.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.78
The EPS has grown by 10% YoY
The equity is down by 44% YoY and by 16% from the previous quarter
BOLT's P/B is 33% below its last 4 quarters average of 0.4
The stock's P/S is 48% less than its last 4 quarters average of 3.8
The revenue rose by 36% YoY but it fell by 12% QoQ
Efficiency
How efficient is Bolt Biotherapeutics business performance
The ROE fell by 46% YoY and by 13% QoQ
Bolt Biotherapeutics's ROA has decreased by 37% YoY and by 11% from the previous quarter
Bolt Biotherapeutics's ROIC has decreased by 37% YoY and by 11% from the previous quarter
The ROS has grown by 33% YoY but it has contracted by 12% from the previous quarter
Dividends
What is BOLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BOLT.
Financial health
How did Bolt Biotherapeutics financials performed over time
The total assets is 193% greater than the total liabilities
The quick ratio has plunged by 53% YoY and by 28% from the previous quarter
The company's current ratio has shrunk by 53% YoY and by 26% QoQ
The debt is 75% less than the equity
BOLT's debt to equity has soared by 56% YoY and by 14% from the previous quarter
The equity is down by 44% YoY and by 16% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.